170 related articles for article (PubMed ID: 8077720)
21. Anticore endotoxin F(ab')2 equine immunoglobulin fragments protect against lethal effects of gram-negative bacterial sepsis.
Dunn DL; Mach PA; Condie RM; Cerra FB
Surgery; 1984 Aug; 96(2):440-6. PubMed ID: 6379963
[TBL] [Abstract][Full Text] [Related]
22. Induction of immunity against lethal Haemophilus influenzae type b infection by Escherichia coli core lipopolysaccharide.
Marks MI; Ziegler EJ; Douglas H; Corbeil LB; Braude AI
J Clin Invest; 1982 Apr; 69(4):742-9. PubMed ID: 7042755
[TBL] [Abstract][Full Text] [Related]
23. Estimation of protective levels of anti-O-specific lipopolysaccharide immunoglobulin G antibody against experimental Escherichia coli infection.
Schiff DE; Wass CA; Cryz SJ; Cross AS; Kim KS
Infect Immun; 1993 Mar; 61(3):975-80. PubMed ID: 7679376
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibodies specific for Escherichia coli J5 lipopolysaccharide: cross-reaction with other gram-negative bacterial species.
Mutharia LM; Crockford G; Bogard WC; Hancock RE
Infect Immun; 1984 Sep; 45(3):631-6. PubMed ID: 6381310
[TBL] [Abstract][Full Text] [Related]
25. Antigenic and immunogenic differences in lipopolysaccharides of Escherichia coli J5 vaccine strains of different origins.
Appelmelk BJ; Maaskant JJ; Verweij-van Vught AM; van der Meer NM; Thijs BG; MacLaren DM
J Gen Microbiol; 1993 Nov; 139(11):2641-7. PubMed ID: 7506295
[TBL] [Abstract][Full Text] [Related]
26. Protection of mice against P. aeruginosa infections by large-scale affinity-purified human IgG specific to P. aeruginosa outer membrane proteins.
Lee NG; Jung SB; Ahn BY; Kim YG; Lee Y; Jeon YJ; Park WJ
Vaccine; 1999 Nov; 18(7-8):665-74. PubMed ID: 10547426
[TBL] [Abstract][Full Text] [Related]
27. Antibody to cell wall glycolipid of Gram-negative bacteria: induction of immunity to bacteremia and endotoxemia.
Braude AI; Ziegler EJ; Douglas H; McCutchan JA
J Infect Dis; 1977 Aug; 136 Suppl():S167-73. PubMed ID: 330776
[TBL] [Abstract][Full Text] [Related]
28. Demonstration of cross-reactive antibodies to smooth gram-negative bacteria in antiserum to Escherichia coli J5.
Baumgartner JD; O'Brien TX; Kirkland TN; Glauser MP; Ziegler EJ
J Infect Dis; 1987 Jul; 156(1):136-43. PubMed ID: 2439613
[TBL] [Abstract][Full Text] [Related]
29. Production and characterisation of mouse monoclonal antibodies reacting with the lipopolysaccharide core region of gram-negative bacilli.
Appelmelk BJ; Verweij-van Vught AM; Maaskant JJ; Schouten WF; De Jonge AJ; Thijs LG; Maclaren DM
J Med Microbiol; 1988 Jun; 26(2):107-14. PubMed ID: 2455054
[TBL] [Abstract][Full Text] [Related]
30. Complement activating and opsonic capacity of monoclonal antibodies raised against Escherichia coli O111 and its rough mutant J5.
Vreede RW; Leuvenink J; Bouter AS; Brouwer EC; Marcelis JH; Verhoef J
Eur J Clin Microbiol; 1986 Apr; 5(2):141-7. PubMed ID: 3522225
[TBL] [Abstract][Full Text] [Related]
31. Immunization of dairy cows with an Escherichia coli J5 lipopolysaccharide vaccine.
Tomita GM; Todhunter DA; Hogan JS; Smith KL
J Dairy Sci; 1995 Oct; 78(10):2178-85. PubMed ID: 8598402
[TBL] [Abstract][Full Text] [Related]
32. Endotoxin neutralization with rabbit antisera to Escherichia coli J5 and other gram-negative bacteria.
Warren HS; Novitsky TJ; Bucklin A; Kania SA; Siber GR
Infect Immun; 1987 Jul; 55(7):1668-73. PubMed ID: 3298063
[TBL] [Abstract][Full Text] [Related]
33. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal study of antibody response to lipopolysaccharides during chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
Fomsgaard A; Høiby N; Shand GH; Conrad RS; Galanos C
Infect Immun; 1988 Sep; 56(9):2270-8. PubMed ID: 3410536
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy of gram-negative bacterial sepsis: enhanced survival in a guinea pig model by use of rabbit antiserum to Escherichia coli J5.
Dunn DL; Ferguson RM
Surgery; 1982 Aug; 92(2):212-9. PubMed ID: 7048594
[TBL] [Abstract][Full Text] [Related]
36. Cross-reactivity of monoclonal antibodies against lipopolysaccharides of gram-negative bacteria.
de Jongh-Leuvenink J; Bouter AS; Marcelis JH; Schellekens J; Verhoef J
Eur J Clin Microbiol; 1986 Apr; 5(2):148-51. PubMed ID: 2424754
[TBL] [Abstract][Full Text] [Related]
37. R-form lipopolysaccharides (LPS) of Gram-negative bacteria as possible vaccine antigens.
Stanislavsky ES; Makarenko TA; Kholodkova EV; Lugowski C
FEMS Immunol Med Microbiol; 1997 Jul; 18(3):139-45. PubMed ID: 9271164
[TBL] [Abstract][Full Text] [Related]
38. Seroprevalence of antibodies against gram-negative core antigens in rabbits, using an Escherichia coli J5 antigen-capture enzyme-linked immunosorbent assay.
Ruble RP; Cullor JS; Brooks DL
Am J Vet Res; 1999 Apr; 60(4):501-6. PubMed ID: 10211696
[TBL] [Abstract][Full Text] [Related]
39. Immunization against nosocomial infection.
Braude AI; Ziegler EJ; McCutchan JA; Douglas H
Am J Med; 1981 Feb; 70(2):463-6. PubMed ID: 7008592
[TBL] [Abstract][Full Text] [Related]
40. Shielding Effect of Escherichia coli O-Antigen Polysaccharide on J5-Induced Cross-Reactive Antibodies.
Rainard P; Repérant-Ferter M; Gitton C; Germon P
mSphere; 2021 Jan; 6(1):. PubMed ID: 33504665
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
